We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio
Read MoreHide Full Article
Phibro Animal Health Corporation (PAHC - Free Report) has been gaining on robust growth in its Performance Products arm. Better-than-expected results for the third quarter of fiscal 2021 and a bullish fourth-quarter 2021 outlook provided by the company buoy optimism. However, downsides may result from a stiff competitive landscape. Also, contraction of both margins is worrying.
Over the past six months, this Zacks Rank #2 (Buy) stock has gained 49.4% versus 5.9% growth of the industry and 14.7% rise of the S&P 500.
The renowned global diversified animal health and mineral nutrition company has a market capitalization of $1.17 billion. The company projects 10.6% growth for the next five years and expects to maintain strength in its business arms. Phibro surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 8.70%.
Let’s delve deeper.
Strong Q3 Results: Phibro exited third-quarter fiscal 2021 with better-than-expected earnings results. Solid growth in the Performance Products segment driven by strong demand for copper-based products drove top-line growth. Growth in international market of dairy products amid the post-pandemic recovery is impressive. The year-over-year growth in the Mineral Nutrition arm is encouraging as well. The outlook for fourth-quarter fiscal 2021 provided by the company is indicative of this bullish trend.
Diversified Product Portfolio: Phibro is focused on expanding its footprint in the poultry, swine and cattle industries, in both domestic and international markets. Phibro is working actively to expand the cattle markets in the United States, specifically in Mexico and Brazil, as well as in Canada, Australia and South Africa. Also, the company recently signed an agreement with Virbac to distribute its generic DRAXXIN in the Canadian market. Phibro is also evaluating potential opportunities in the oral space for cats and dogs, a space with an estimated addressable market of more than $2 billion.
Potential in Emerging Markets: In the third quarter of fiscal 2021, Phibro registered growth in nutritional specialties driven by strong international growth in dairy products. Moreover, vaccine sales were primarily driven by growth in APAC and North America regions.
Currently, the company is expanding its dairy business in the markets of Australia, Brazil and Mexico. We believe given the turmoil that is currently prevailing in the economies of Russia, Greece, Brazil and China, Phibro has performed quite well of late and bears the potential to maintain the healthy performance, going ahead.
However, downsides might result from Phibro’s operation in a highly competitive industry, which includes both global and regional competitors. Moreover, consolidation continues to rise in the animal health market, which might work in favor of Phibro’s competitors.
Further, during the third quarter of fiscal 2021, the company witnessed decline in vaccine sales due to challenging economic conditions in Eastern Europe. Further, contraction of both margins does not bode well.
Estimate Trend
Phibro has been witnessing a positive estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings per share (EPS) has moved 6.8% north to $1.26.
The Zacks Consensus Estimate for fourth-quarter fiscal 2021 EPS is pegged at 32 cents, suggesting a rise of 88.2% from the year-ago reported number.
National Vision has a projected long-term earnings growth rate of 23%.
Boston Scientific has a projected long-term earnings growth rate of 9%.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Image: Bigstock
Here's Why You Should Add Phibro (PAHC) to Your Portfolio
Phibro Animal Health Corporation (PAHC - Free Report) has been gaining on robust growth in its Performance Products arm. Better-than-expected results for the third quarter of fiscal 2021 and a bullish fourth-quarter 2021 outlook provided by the company buoy optimism. However, downsides may result from a stiff competitive landscape. Also, contraction of both margins is worrying.
Over the past six months, this Zacks Rank #2 (Buy) stock has gained 49.4% versus 5.9% growth of the industry and 14.7% rise of the S&P 500.
The renowned global diversified animal health and mineral nutrition company has a market capitalization of $1.17 billion. The company projects 10.6% growth for the next five years and expects to maintain strength in its business arms. Phibro surpassed estimates in three of the trailing four quarters and missed the same in one, the average surprise being 8.70%.
Let’s delve deeper.
Strong Q3 Results: Phibro exited third-quarter fiscal 2021 with better-than-expected earnings results. Solid growth in the Performance Products segment driven by strong demand for copper-based products drove top-line growth. Growth in international market of dairy products amid the post-pandemic recovery is impressive. The year-over-year growth in the Mineral Nutrition arm is encouraging as well. The outlook for fourth-quarter fiscal 2021 provided by the company is indicative of this bullish trend.
Diversified Product Portfolio: Phibro is focused on expanding its footprint in the poultry, swine and cattle industries, in both domestic and international markets. Phibro is working actively to expand the cattle markets in the United States, specifically in Mexico and Brazil, as well as in Canada, Australia and South Africa. Also, the company recently signed an agreement with Virbac to distribute its generic DRAXXIN in the Canadian market. Phibro is also evaluating potential opportunities in the oral space for cats and dogs, a space with an estimated addressable market of more than $2 billion.
Potential in Emerging Markets: In the third quarter of fiscal 2021, Phibro registered growth in nutritional specialties driven by strong international growth in dairy products. Moreover, vaccine sales were primarily driven by growth in APAC and North America regions.
Currently, the company is expanding its dairy business in the markets of Australia, Brazil and Mexico. We believe given the turmoil that is currently prevailing in the economies of Russia, Greece, Brazil and China, Phibro has performed quite well of late and bears the potential to maintain the healthy performance, going ahead.
However, downsides might result from Phibro’s operation in a highly competitive industry, which includes both global and regional competitors. Moreover, consolidation continues to rise in the animal health market, which might work in favor of Phibro’s competitors.
Further, during the third quarter of fiscal 2021, the company witnessed decline in vaccine sales due to challenging economic conditions in Eastern Europe. Further, contraction of both margins does not bode well.
Estimate Trend
Phibro has been witnessing a positive estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings per share (EPS) has moved 6.8% north to $1.26.
The Zacks Consensus Estimate for fourth-quarter fiscal 2021 EPS is pegged at 32 cents, suggesting a rise of 88.2% from the year-ago reported number.
Other Key Picks
A few similar-ranked stocks from the broader medical space are National Vision Holdings, Inc. (EYE - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Envista Holdings Corporation (NVST - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
National Vision has a projected long-term earnings growth rate of 23%.
Boston Scientific has a projected long-term earnings growth rate of 9%.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>